Effect of Endoplasmic Reticulum Stress on Metabolic Function

Completed · Not applicable · Has a placebo group

Conditions studied: Insulin Resistance, Diabetes, Obesity

In brief

Normally, the hormone insulin works to help keep blood sugar normal. However, as a person gains weight, insulin does not work as well and blood sugar tends to be a little higher than normal. This is called "insulin resistance". Two investigational drugs (not approved by the Food and Drug Administration) for the treatment of high lipid levels or insulin resistance are being examined in this study: one drug is called tauroursodeoxycholic acid (TUDCA), the other is called sodium phenylbutyrate (PBA). This study is designed to test if TUDCA and/or PBA is effective in people who are obese with insulin resistance and high lipids. We hypothesize that pharmacologically-induced decreases in ER stress will improve insulin action and hepatic lipid metabolism in obese subjects.

Key facts

Study ID

NCT00771901

Run by

Washington University School of Medicine

People needed

101

Starts

2008-02-01

Expected to finish

2014-12-01

Last updated by the study team

2018-05-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• BMI range 30 to 45
• sedentary (defined as regular exercise < 1 h per week or < 2 x/week for the last 6 months)

You may not qualify if…

• active or previous infection with hepatitis B or C
• liver diseases
• history of alcohol abuse
• current alcohol consumption > 20 g/day
• severe hypertriglyceridemia ( > 400 mg/dL)
• active peptic ulcer disease
• taking cholestyramine or oral contraceptives
• women who are pregnant or lactating

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.